Breast cancer ADCs: choosing a treatment and understanding sacituzumab tirumotecan

Antibody-drug conjugates, or ADCs, attach a cell-killing medicine to an antibody that recognizes a target on cancer cells. In breast cancer, the relevant ADC depends on HER2 expression, hormone receptors and previous treatment. Sacituzumab tirumotecan is a TROP2-directed ADC with approved breast cancer indications in China. It is a different medicine from sacituzumab govitecan. The treatment decision should compare the exact drug, eligibility, expected benefit and safety needs with your remaining options.

By eastmedgo editorial · October 5, 2026

On this page

Why an ADC is more than an antibody alone

An ADC combines an antibody, a linker and a cytotoxic payload. The antibody helps deliver the payload to cells with the relevant target. Different ADCs can use different targets or payloads, which affects where they are useful and what side effects need attention.

Ask for the full generic name when discussing treatment. An abbreviation or brand name can obscure the difference between medicines. Keep the drug and treatment dates in your record, especially if you later seek another opinion or change hospitals.

Sources and references: [1] [2]

Match the drug to the current cancer findings

HER2-positive, HER2-low and hormone receptor-defined disease can lead to different ADC discussions. The exact HER2 score, confirmatory testing and prior treatment history may be required. Some indications also depend on whether disease is unresectable or metastatic.

Ask which report establishes eligibility and whether the specimen still reflects the current disease. If an old report only says HER2-negative, the pathologist may need to clarify the score. The purpose is to identify a useful treatment option, not simply to repeat testing.

Sources and references: [2] [3]

Previous treatment changes the comparison

An ADC may be used in a particular postoperative or advanced-disease setting according to its evidence and indication. Previous chemotherapy, endocrine treatment, anti-HER2 treatment and earlier ADCs all matter when choosing the next drug.

Ask why this ADC is preferred at this point and what the next option would be if it is ineffective or poorly tolerated. Similar targets do not make drugs interchangeable, and benefit from one ADC does not establish the benefit of another after resistance.

Sources and references: [2] [1]

Where sacituzumab tirumotecan is approved in China

China has approved sacituzumab tirumotecan for adults with unresectable locally advanced or metastatic TNBC after at least two systemic therapies, including at least one for advanced or metastatic disease. It also has a Chinese indication for unresectable or metastatic HR-positive, HER2-negative breast cancer after endocrine therapy and at least one chemotherapy line for advanced disease.

These are specific clinical pathways. The receiving oncologist needs to check the subtype, HER2 report and treatment history against the applicable indication and prescribing information. An approved indication creates an option to assess; prescription arrangements and monitoring still need to be organized for the individual.

Sources and references: [4]

What the TNBC trial contributes

The randomized OptiTROP-Breast01 trial compared sacituzumab tirumotecan with chemotherapy in previously treated locally recurrent or metastatic TNBC. It reported improved progression-free survival in that population. Blood-related toxicity was the most common treatment-related adverse event described in the abstract.

This evidence supports a discussion for a matching patient. Earlier treatment lines, a different breast cancer subtype or a combination with another drug require their own evidence. Ask which data support the exact plan offered to you.

Sources and references: [5]

Compare side effects by the individual ADC

ADCs can cause low blood counts, nausea, fatigue or other effects from their payloads. Important risks differ by medicine. Trastuzumab deruxtecan, for example, needs particular attention to lung inflammation. A safety plan for one ADC should not be assumed to fit another.

Ask about the blood-test schedule, preventive medicines and urgent symptoms. Report fever, significant diarrhea or new breathing symptoms promptly according to the unit's instructions. Bring a history of persistent neuropathy, lung disease and serious reactions to previous treatment.

Sources and references: [2] [1] [5]

Clarify the complete treatment arrangement

Ask how often infusions occur, when scans are planned and who handles problems between visits. If you will receive treatment away from home, discuss the time needed near the hospital and how laboratory results are shared afterward.

A useful cost discussion separates the medicine from infusion charges, tests, supportive care and coordination. Request the proposed regimen in writing before comparing quotations. If access is through a clinical trial, the study team should explain which parts are research and what expenses remain yours.

Sources and references: [2] [6]

A Shanghai review of your ADC options

Fudan University Shanghai Cancer Center has a breast cancer multidisciplinary service. A consultation can review the current subtype and where an ADC fits among the remaining treatments.

EastMedGo can help organize a focused inquiry, including a question about sacituzumab tirumotecan under its Chinese indication. Prepare the receptor reports, recent images and every previous treatment with dates. We can clarify the service's assessment and appointment process and discuss coordination costs before travel.

Sources and references: [7] [4]

Common questions

Are sacituzumab tirumotecan and sacituzumab govitecan the same drug?

No. They are distinct ADCs with their own evidence, indications and prescribing requirements. Use the full generic name in appointment inquiries and treatment records.

Sources and references: [4] [1]

Does a TROP2-directed ADC require the same testing as a HER2-directed ADC?

The requirements depend on the particular drug and indication. Ask which pathology or biomarker result is needed for the proposed treatment instead of assuming one universal ADC test.

Sources and references: [1] [4]

Can a Chinese approval establish that a Shanghai hospital has the medicine ready?

Approval identifies the permitted clinical setting. The receiving service must separately confirm prescribing assessment, supply and the monitoring arrangement for your care.